No Data
No Data
Cathay Biotech's (SHSE:688065) Anemic Earnings Might Be Worse Than You Think
Cathay Biotech's H1 Profit Rises 2%, Revenue Jumps 40%; Shares Down 3%
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Cathay Biotech Inc. (688065.SH) has completed the repurchase of 0.9778 million shares, cost 50.4258 million yuan.
Cathay Biotech Inc. (688065.SH) announced that as of the date of this announcement, the company has completed the repurchase and has actually bought back...
Cathay Biotech Inc. (688065.SH): net income in the first half of the year was 0.247 billion yuan, an increase of 2.31% year-on-year.
On August 15th, Gelon Hui reported that Cathay Biotech Inc. (688065.SH) released its 2024 interim report, achieving revenue of 1.444 billion yuan, a year-on-year increase of 40.16%; net income attributable to shareholders of the listed company was 0.247 billion yuan, a year-on-year increase of 2.31%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.24 billion yuan, a year-on-year increase of 11.34%; basic earnings per share were 0.42 yuan. During the reporting period, the company's revenue increased by 40.16% year-on-year, which was mainly due to the company seizing market opportunities, increasing product sales, and launching new products.
No Data
No Data